---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（201883001552734.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文替Brevibloc处方资料（仅供参考）

适应症和用法

Brevibloc（艾司洛尔盐酸盐）适用于围手术期，术后或其他急需情况下心房颤动或心房扑动患者心室率的快速控制，其中需要用短效剂短期控制心室率。 Brevibloc（艾司洛尔盐酸盐）不适用于预期转移到另一种药物的慢性环境中。 Brevibloc（艾司洛尔盐酸盐）也适用于术中和术后心动过速和/或高血压。

重要风险信息

窦性心动过缓，心脏阻滞大于一度，心源性休克或明显心力衰竭的患者禁用。

在输注过程中要小心使用并仔细监测LV功能障碍，CHF，低血压，反应性气道疾病和糖尿病患者。一般而言，支气管痉挛性疾病患者不应接受β受体阻滞剂。由于相对β1的选择性和可滴定性，在患有支气管痉挛疾病的患者中可以谨慎使用艾司洛尔HCl。滴定至尽可能低的剂量。

不应用于治疗高血压，主要是由于与低温有关的血管收缩或预防心动过速和/或高血压。

最常见的副作用是低血压;无症状（25％）和症状（12％），主要是头晕和发汗。低血压通常在剂量减少或输注终止后30分钟内逆转。输液部位反应（8％）。

Indications & Usage

Brevibloc (esmolol HCl) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Brevibloc (esmolol HCl) is not intended for use in chronic settings where transfer to another agent is anticipated. Brevibloc (esmolol HCl) is also indicated for intraoperative and postoperative tachycardia and/or hypertension.

Important Risk Information

Contraindicated in patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, or overt cardiac failure.

Use with caution and monitor carefully during infusion for patients with LV dysfunction, CHF, hypotension, reactive airway disease, and diabetes. In general, patients with bronchospastic disease should not receive beta blockers. Due to the relative beta1 selectivity and titratability, esmolol HCl may be used with caution in patients with bronchospastic disease. Titrate to the lowest possible dose.

Should not be used for treatment of hypertension due primarily to vasoconstriction associated with hypothermia or to prevent tachycardia and/or hypertension.

The most common side effect was hypotension; asymptomatic (25%) and symptomatic (12%), mainly dizziness and diaphoresis. Hypotension usually reverses within 30 minutes of decrease of dose or termination of infusion. Infusion site reactions (8%).

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（201883001552734.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------

2011-4-7更新